Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 4, 2012

View Archived Issues

New vaccines for dengue virus presented by Merck & Co.

New diagnostic agents for cancer designed by Bayer Schering Pharma

Roche patents new glucokinase activators for diabetes

Dual PI3K/mTOR inhibitors prove active in glioblastoma cells

Proof-of-concept of a novel enzyme-based drug delivery system

Favorable safety observed for BI-853520 in phase I study

FORMA Therapeutics divulges novel NAmPRTase inhibitors

New Zealand and U.S. researchers present new antimalarial agents

Merck & Co. prepares new agents for hypertension

New bromodomain-containing protein inhibitors disclosed by GlaxoSmithKline

Phase I data presented for PF-04449913 in advanced solid tumors

Rapid antidepressant effects seen for AZD-6765 in patients

Cellceutix updates on Kevetrin trial

Merck begins phase II/III MK-8931 study

Clinical program commences for reformulated muscle relaxant Metaxalone SoluMatrix

Novartis launches Xolair for s.c. injection 75 mg in Japan

Theravectys receives clearance for first human trial of anti-HIV vaccine

Optimer Pharmaceuticals and AstraZeneca collaborate on fidaxomicin

Ryzodeg passes First Committee on Drugs of Pharmaceutical Affairs review in Japan

Galapagos opens GLPG-0634 IND in the U.S.

PharmaEssentia acquires certain rights to KX-01 in Asia

MSD K.K. files for approval of insomnia agent in Japan

Tracleer obtains additional indication approval in Japan

Canadian authorities assessing reimbursement for newly approved cystic fibrosis treatment Kalydeco

Synthetic Biologics acquires beta-lactamase compounds from Prev AbR

Altravax receives grant from NIH to develop vaccines for HIV/AIDS

Horizon Pharma launches novel prednisone formulation in the U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.